SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...
SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...
Immune checkpoint inhibitors (ICIs) have transformed oncology, enabling patients with previously untreatable malignancies to achieve durable responses. However, as the use of agents such as ...
A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses ...
A real-world analysis investigates the impact of concurrent GLP-1 RA use on long-term survival and the safety profile of patients with solid and hematologic malignancies receiving immune checkpoint ...
SER-155 is an oral live biotherapeutic being investigated to treat disruptive conditions of the gastrointestinal tract. In a ...
Gastrointestinal side effects are among the most important issues to address with patients starting on immune checkpoint ...
A team of researchers from VCU Massey Comprehensive Cancer Center, the VCU School of Dentistry and the University of ...
A new study from University Hospitals Connor Whole Health reports that an insurance-supported integrative oncology program ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Subcutaneous isatuximab is now approved with pomalidomide/dexamethasone, carfilzomib/dexamethasone, and bortezomib/lenalidomide/dexamethasone, aligning SC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results